OBJECTIVES: This article presents a methodological framework for developing health economic models of whole systems of disease and treatment pathways to inform decisions concerning resource allocation-an approach referred to as "Whole Disease Modeling." This system-level approach can provide a consistent mathematical infrastructure for the economic evaluation of virtually any intervention across a disease pathway. METHODS: The framework has been developed for cancer but is broadly generalizable to other diseases. It has been informed by pilot work, a systematic review of economic analyses, a qualitative examination of model development processes, and other literature from the fields of operational research, statistics, and health economics. RESULTS: The framework is built on three principles: 1) the model boundary and breadth should capture all relevant aspects of the disease and its treatment-from preclinical disease through to death, 2) the model should be developed such that the decision node is conceptually transferable across the model, and 3) the costs and consequences of service elements should be structurally related. A generalized process for developing Whole Disease Models is presented. DISCUSSION: Although this approach involves a nontrivial investment of time and resource, its value may be realized when 1) multiple options for service change require economic analysis at a single time point, 2) a disease service changes rapidly and the model can be reused, 3) current services within a pathway have not been subjected to economic analysis, 4) upstream events are expected to have important downstream effects, or 5) simple cost-utility decision rules fail to reflect the complexity of the decision-makers' objectives.
OBJECTIVES: This article presents a methodological framework for developing health economic models of whole systems of disease and treatment pathways to inform decisions concerning resource allocation-an approach referred to as "Whole Disease Modeling." This system-level approach can provide a consistent mathematical infrastructure for the economic evaluation of virtually any intervention across a disease pathway. METHODS: The framework has been developed for cancer but is broadly generalizable to other diseases. It has been informed by pilot work, a systematic review of economic analyses, a qualitative examination of model development processes, and other literature from the fields of operational research, statistics, and health economics. RESULTS: The framework is built on three principles: 1) the model boundary and breadth should capture all relevant aspects of the disease and its treatment-from preclinical disease through to death, 2) the model should be developed such that the decision node is conceptually transferable across the model, and 3) the costs and consequences of service elements should be structurally related. A generalized process for developing Whole Disease Models is presented. DISCUSSION: Although this approach involves a nontrivial investment of time and resource, its value may be realized when 1) multiple options for service change require economic analysis at a single time point, 2) a disease service changes rapidly and the model can be reused, 3) current services within a pathway have not been subjected to economic analysis, 4) upstream events are expected to have important downstream effects, or 5) simple cost-utility decision rules fail to reflect the complexity of the decision-makers' objectives.
Authors: Talitha Feenstra; Isaac Corro-Ramos; Dominique Hamerlijnck; George van Voorn; Salah Ghabri Journal: Pharmacoeconomics Date: 2021-12-16 Impact factor: 4.981
Authors: Jonathan Tosh; Ben Kearns; Alan Brennan; Glenys Parry; Thomas Ricketts; David Saxon; Alexis Kilgarriff-Foster; Anna Thake; Eleni Chambers; Rebecca Hutten Journal: BMC Health Serv Res Date: 2013-04-26 Impact factor: 2.655
Authors: Vojtěch Kamenský; Vladimír Rogalewicz; Ondřej Gajdoš; Gleb Donin Journal: Int J Environ Res Public Health Date: 2022-09-19 Impact factor: 4.614
Authors: Alessandra Buja; Giulia Pasello; Marco Schiavon; Giuseppe De Luca; Michele Rivera; Claudia Cozzolino; Anna De Polo; Manuela Scioni; Alberto Bortolami; Vincenzo Baldo; PierFranco Conte Journal: Thorac Cancer Date: 2022-08-15 Impact factor: 3.223
Authors: Alessandra Buja; Michele Rivera; Anna De Polo; Eugenio di Brino; Marco Marchetti; Manuela Scioni; Giulia Pasello; Alberto Bortolami; Vincenzo Rebba; Marco Schiavon; Fiorella Calabrese; Giovanni Mandoliti; Vincenzo Baldo; PierFranco Conte Journal: Thorac Cancer Date: 2020-11-21 Impact factor: 3.500